Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.83 |
| ▸ | GNA15 | P30679 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521232 | 1.00 | FFAR1 (0.83) | FFAR1GNA15 | |
| SCHEMBL4740233 | 1.00 | FFAR1 (0.83) | FFAR1GNA15 | |
| SCHEMBL12191648 | 0.91 | FFAR1 (0.86) | FFAR1GNA15 | |
| SCHEMBL13118205 | 0.91 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL3553422 | 0.91 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL12194429 | 0.91 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL29367214 | 0.91 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL3518942 | 0.90 | FFAR1 (0.98) | FFAR1GNA15 | |
| SCHEMBL3518944 | 0.90 | FFAR1 (0.84) | FFAR1GNA15 | |
| SCHEMBL5297901 | 0.90 | FFAR1 (0.98) | FFAR1GNA15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | FFAR1 549/4885GNA15 3737/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | FFAR1 699/4885GNA15 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.